Neurizon Therapeutics Limited (ASX: NUZ), formerly known as PharmAust, is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease.  Neurizon strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001’s potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. 

Biotechnology

Neuroscience

Therapeutics

Neurizon

Neurizon's headquarters in South Melbourne, Australia

Michael Thurn

Lidija Damjanovic

Paul Field

Kathryn W.

John Clark

Dan O'Connell

This department oversees governance and strategic direction for the organization.

Board Leadership

This department oversees organizational operations and ensures adherence to regulatory standards.

Neurizon

Org chart

Teams

Board Leadership

Operations and Compliance

Offices

Neurizon

Org chart

Teams

Board Leadership

Operations and Compliance

Offices

Related companies